RxDoctor Payments Data

Carlos Soto, MD

Family Medicine · Columbia, SCNPI 1699787689

Payments from drug & device makers

$9,937in general payments, 2019–2025

Across 601 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Medtronic$1K
  • AbbVie$956
  • Johnson & Johnson$835
  • GSK$739
  • AstraZeneca$627
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$1,10011%
  • Food & beverage$8,83789%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,937 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$208,423
Medicare patients
227
Services billed
8,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide143$200,605
MounjaroTirzepatide85$132,023
FarxigaDapagliflozin Propanediol76$89,629
JardianceEmpagliflozin67$86,766
RybelsusSemaglutide35$74,216
Xigduo XrDapaglifloz Propaned/Metformin58$69,614
TrulicityDulaglutide42$56,774
XareltoRivaroxaban36$42,610
Synjardy XrEmpagliflozin/Metformin Hcl34$39,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$33,043
EliquisApixaban24$30,261
LinzessLinaclotide20$28,060
Repatha SureclickEvolocumab15$11,952
Breo ElliptaFluticasone/Vilanterol24$9,538
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt13$7,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,283$274,821178 claims
Lilly USA, LLCMounjaro, Trulicity$369$188,796127 claims
Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat$262$131,406112 claims
AstraZenecaFarxiga$627$89,62976 claims
Johnson & JohnsonXarelto$835$42,61036 claims
GSKTrelegy Ellipta, Breo Ellipta$739$42,58162 claims
PfizerEliquis$338$30,26124 claims
AbbVieLinzess$956$28,06020 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$94$6,24712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →